載入中
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
前收盤價
US$9.67
−US$0.49 · -4.82%
盤後
US$9.67
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
日內區間
目前US$9.67
52週區間
目前US$9.67
盤中時間採用ET。市場資料可能有所延遲。
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
日內區間
目前US$9.67
52週區間
目前US$9.67
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 280萬 USD | 453.4萬 USD | 571.8萬 USD | 574.7萬 USD | 478.2萬 USD |
| 銷貨成本 | 1174.2萬 USD | 6245.9萬 USD | 4756.7萬 USD | 5890.8萬 USD | 4458.6萬 USD |
| 毛利 | −894.2萬 USD | −5792.5萬 USD | −4184.9萬 USD | −5316.1萬 USD | −3980.4萬 USD |
| 研究與開發 | 8141.8萬 USD | 6385.9萬 USD | 4806.7萬 USD | 5890.8萬 USD | 4458.6萬 USD |
| 銷售、一般及管理費用 | 3505.8萬 USD | — | — | — | — |
| 營業費用 | 1.16億 USD | 5096.3萬 USD | 7366.6萬 USD | 5358.9萬 USD | 3543.4萬 USD |
| 利息支出 | 20.9萬 USD | 56.5萬 USD | 101萬 USD | 97.2萬 USD | 343.2萬 USD |
| 折舊和攤銷 | 1174.2萬 USD | 1338.9萬 USD | 1399.9萬 USD | 1310萬 USD | 665.4萬 USD |
| 營業利益 | −1.25億 USD | −1.09億 USD | −1.16億 USD | −1.07億 USD | −7523.8萬 USD |
| 淨利 | −1.15億 USD | −1.03億 USD | −1.11億 USD | −1.05億 USD | −1.01億 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$13.60
上漲空間 40.64%報告持有此股票曝險的交易所交易基金。
ARK Genomic Revolution ETFARKG1.08億5.05%22.19億 USD0.75%US$49.48-3.55%
State Street SPDR S&P Biotech ETFXBI4947.92萬0.50%103.03億 USD0.35%US$151.4-1.54%
Vanguard Morningstar Total Stock Market ETFVTI4034.32萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM3984.54萬0.05%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF1439.53萬0.01%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO1177.09萬0.08%139.17億 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB1165.97萬0.11%108.2億 USD0.44%US$204.26-1.08%
Schwab U.S. Small-Cap ETFSCHA866.57萬0.04%218.24億 USD0.03%US$32.66-0.40%ARK Genomic Revolution ETFARKGState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
